Sunquest, the Tucson, Arizona-based provider of laboratory information solutions, has announced that it is forming “The HIT Group” to encourage the Food and Drug Administration (FDA) to regulate HIT. There have been increasing indications that the government agency intends to do so. Sunquest supports FDA regulation of HIT as a safeguard of patient safety.
“Innovation is the key to continued progress in our industry,” a Sunquest representative notes. “FDA regulation should be seen as a tool to foster safety-inducing innovation. Reasonable and effective FDA regulation of a high-tech, growing industry such as HIT will foster further innovative progress that will result in measurable and improved patient outcomes.”
The HIT Group will be comprised of members of the HIT industry community that will work to influence regulatory approaches through letters and communication with HHS and all applicable government agencies and offices. It will also share progress on regulation through webinars, and share best practices. Learn more about the HIT Group and why Sunquest believes HIT needs FDA regulation.
